Given BMI1’s central role in NPC malignancy and drug resistance, this study investigates whether BMI1, validated as a transcriptional target of FOXA1 in our research, mediates FOXA1’s effects on NPC progression and cisplatin resistance. This evidence concerns the gene BMI1 and nasopharyngeal carcinoma.